Returnee Female PhD Founder's Cell Therapy Firm Raises Over RMB 210 Million in Series C1 Financing

Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is intended solely for the introduction of medications related to medical health and does not recommend treatment plans (if mentioned); such content does not represent the platform’s position.Authorization is required for any article reprints.

On June 1, iRegene announced the completion ofRMB 210 million Series C1 financing。This round of financing is led byPhotosynthesis VenturesandXingze CapitalCo-lead investment.The funds raised will be primarily used to advance the company’s core clinical pipeline, continuously upgrade the “AI + Chemically Induced” platform, establish a scaled-up production system, and lay out global clinical development and international commercial partnerships.iRegene, founded by Dr. Wei Jun in 2017, is an innovative pharmaceutical company dedicated to the development of small-molecule chemical transcriptional regulation-induced pluripotent stem cell (iPSC) products.

The completion of this round of financing marks iRegene’sAI-driven platform capabilities, clinical pipeline delivery,Age-Related Disease Pipeline，Global Execution Capability and Industrialization Potentialgaining further recognition from leading technology and healthcare investment firms. As its core products enter the accelerated clinical development phase in China and the United States, iRegene is evolving from a single-pipeline-driven company into a platform-based biotech with the capacity for continuous multi-pipeline output and global competitive potential.

Targeting the Large Market for Age-Related Diseases, Strategically Positioning for Long-Term High-Growth Medical Demand

Global population aging is driving profound changes in the disease spectrum. Age-related diseases, represented by Parkinson’s disease, Alzheimer’s disease, multiple system atrophy, retinal degenerative diseases, irreversible visual impairment, diabetes, and other metabolic decline disorders, are becoming one of the core challenges facing future global healthcare systems.

iRegene’s pipeline strategy is centered around this large, long-term market. Starting with neurodegenerative diseases, the company has established a clear platform extension pathway. This means that iRegene’s commercial potential is not limited to a single indication, but rather targets a global disease market driven by population aging, characterized by strong long-term growth certainty and substantial unmet clinical needs.

“AI + Chemical Induction”: ByAI Reconstructs the R&D Paradigm for Cell Therapy

iRegene’s independently developed “AI + Chemical Induction” platform leverages small-molecule compounds to precisely regulate key nodes, thereby enabling efficient, stable, and scalable production of target functional cells. In addition to NouvNeu001, iRegene has established multiple innovative pipelines based on the same “AI + Chemical Induction” platform, gradually forming a product portfolio covering central nervous system disorders, ophthalmic diseases, and other major diseases.

iRegene's Development for Multiple System Atrophy-Parkinsonian TypeNouvNeu004Has entered the stage of synchronized clinical development in China and the United States, further validating the scalability of iRegene’s AI platform in identifying common pathological mechanisms across various neurological diseases, discovering functional cell regulatory pathways, and generating candidate products.

In the field of ophthalmic diseases, the company has strategically focused on irreversible visual function impairment.NouvSightPipeline series. The smooth advancement of this platform is expected to further expand its application boundaries in the field of ophthalmology.

The formation of iRegene’s product portfolio signifies that the company is no longer a single-pipeline entity, but is evolving into a platform-based biotech driven by an AI-powered foundational platform, capable of continuously generating innovative cell therapy products.

Team Execution and Global Innovation in Clinical Development as Key Competitive Advantages

For pioneering companies in new drug development, the ability to transform complex technologies into pharmaceutical products that are acceptable to regulatory authorities, implementable in clinical settings, and understandable to global markets ultimately depends on the team’s systematic execution capabilities. iRegene’s success in advancing its core products into simultaneous clinical development phases in China and the United States, while continuously progressing its multi-pipeline portfolio, demonstrates the management team’s comprehensive mastery of scientific challenges, clinical needs, regulatory pathways, industrialization logic, and capital market dynamics. This strategic choice—originating in China, oriented toward global clinical validation, and proactively engaging in international competition for innovative drugs—reflects the iRegene team’s global vision, innovative courage, and consistent ability to deliver results.

Building a Globally Competitive Universal Cell Therapy Platform Enterprise

CEO of iRegeneDr. Wei JunIndicates：“The completion of this round of financing marks a significant milestone in the development of iRegene. We will continue to center our efforts on the ‘AI + Chemical Induction’ platform, steadily expanding our portfolio of platform-based products. In addressing major diseases that remain inadequately treated worldwide, we aim to propel China’s original cell therapies onto the global stage through more efficient execution, a more open global perspective, and more pioneering clinical development strategies.”

Gao Jiankai, Partner at Guanghe Venture Capital, stated:“Leveraging AI-enabled chemically induced regenerative medicine technology, iRegene effectively addresses many of the pain points associated with traditional cell therapies. The founding team has deep expertise in the field of cellular induction, with years of experience and world-class R&D capabilities. Building on its technological foundation, the team has established a comprehensive product pipeline matrix, with multiple programs advancing at the forefront of the industry, thereby creating strong competitive barriers. Amid the global trend of population aging, the market for treating age-related diseases is expanding into a vast opportunity worth hundreds of billions. We look forward to the company’s continued breakthroughs in technology and clinical applications for major age-related diseases, solidifying its leading position in the industry.”

Wang Zhiqiao, Vice President of Guanghe Ventures, stated:“iRegene is a platform-based biotech company with significant potential in the field of regenerative medicine, and has already demonstrated globally leading potential and efficient execution capabilities in its first-in-class pipeline at the clinical stage. We believe that there is a vast unmet clinical need in the aging sector worldwide, and we look forward to iRegene continuously delivering high-quality pipelines and creating profound social value.”

Dr. Wei Ding, Partner at Xingze Capital, stated:“We highly recognize the company’s proprietary ‘AI + Chemical Induction’ universal cell therapy platform. iRegene has not only rapidly advanced its core Parkinson’s disease pipeline, NouvNeu001, into Phase II clinical trials in both China and the United States, but also continues to deliver global first-in-class assets for major diseases such as multiple system atrophy and retinal degenerative diseases. This robust platform capability combined with exceptional execution efficiency is the core reason for our firm increased investment in this round. We look forward to the company continuing to lead the next generation of regenerative medicine and benefiting patients worldwide at an early date.”